Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Maurizio Memo
Based on 3 articles published since 2010
(Why 3 articles?)
||||

Between 2010 and 2020, Maurizio Memo wrote the following 3 articles about Parkinson Disease.
 
+ Citations + Abstracts
1 Review Using iPS Cells toward the Understanding of Parkinson's Disease. 2015

Torrent, Roger / De Angelis Rigotti, Francesca / Dell'Era, Patrizia / Memo, Maurizio / Raya, Angel / Consiglio, Antonella. ·Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona Science Park, Barcelona 08028, Spain. rtorrent@gmail.com. · Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona Science Park, Barcelona 08028, Spain. fdeangelisrigotti@ibub.pcb.ub.es. · Department of Molecular and Translational Medicine, Fibroblast Reprogramming Unit, University of Brescia, Brescia 25123, Italy. patrizia.dellera@med.unibs.it. · Department of Molecular and Translational Medicine, Fibroblast Reprogramming Unit, University of Brescia, Brescia 25123, Italy. maurizio.memo@med.unibs.it. · Control of Stem Cell Potency Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, Spain. araya@ibecbarcelona.eu. · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain. araya@ibecbarcelona.eu. · Center for Networked Biomedical Research on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain. araya@ibecbarcelona.eu. · Center of Regenerative Medicine in Barcelona, Dr. Aiguader 88, Barcelona 08003, Spain. araya@ibecbarcelona.eu. · Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona Science Park, Barcelona 08028, Spain. aconsiglio@ibub.pcb.ub.es. · Department of Molecular and Translational Medicine, Fibroblast Reprogramming Unit, University of Brescia, Brescia 25123, Italy. aconsiglio@ibub.pcb.ub.es. ·J Clin Med · Pubmed #26239346.

ABSTRACT: Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) represents an efficient tool for in vitro modeling of human brain diseases and provides an innovative opportunity in the identification of new therapeutic drugs. Patient-specific iPSC can be differentiated into disease-relevant cell types, including neurons, carrying the genetic background of the donor and enabling de novo generation of human models of genetically complex disorders. Parkinson's disease (PD) is the second most common age-related progressive neurodegenerative disease, which is mainly characterized by nigrostriatal dopaminergic (DA) neuron degeneration and synaptic dysfunction. Recently, the generation of disease-specific iPSC from patients suffering from PD has unveiled a recapitulation of disease-related cell phenotypes, such as abnormal α-synuclein accumulation and alterations in autophagy machinery. The use of patient-specific iPSC has a remarkable potential to uncover novel insights of the disease pathogenesis, which in turn will open new avenues for clinical intervention. This review explores the current Parkinson's disease iPSC-based models highlighting their role in the discovery of new drugs, as well as discussing the most challenging limitations iPSC-models face today.

2 Review Induced pluripotent stem cell-based studies of Parkinson's disease: challenges and promises. 2013

Sanchez-Danes, Adriana / Benzoni, Patrizia / Memo, Maurizio / Dell'Era, Patrizia / Raya, Angel / Consiglio, Antonella. ·Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona Science Park, Baldiri Reixac 15-21, 08028 Barcelona, Spain. aconsiglio@pcb.ub.es. ·CNS Neurol Disord Drug Targets · Pubmed #24040813.

ABSTRACT: A critical step in the development of effective therapeutics to treat Parkinson's disease (PD) is the identification of molecular pathogenic mechanisms underlying this chronically progressive neurodegenerative disease. However, while animal models have provided valuable information about the molecular basis of PD, the lack of faithful cellular and animal models that recapitulate human pathophysiology is delaying the development of new therapeutics. The reprogramming of somatic cells to induced pluripotent stem cells (iPSC) using delivery of defined combinations of transcription factors is a groundbreaking discovery that opens great opportunities for modeling human diseases, including PD, since iPSC can be generated from patients and differentiated into disease-relevant cell types, which would capture the patients' genetic complexity. Furthermore, human iPSC-derived neuronal models offer unprecedented access to early stages of the disease, allowing the investigation of the events that initiate the pathologic process in PD. Recently, human iPSC-derived neurons from patients with familial and sporadic PD have been generated and importantly they recapitulate some PD-related cell phenotypes, including abnormal α-synuclein accumulation in vitro, and alterations in the autophagy machinery. This review highlights the current PD iPSC-based models and discusses the potential future research directions of this field.

3 Article Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. 2012

Sánchez-Danés, Adriana / Richaud-Patin, Yvonne / Carballo-Carbajal, Iria / Jiménez-Delgado, Senda / Caig, Carles / Mora, Sergio / Di Guglielmo, Claudia / Ezquerra, Mario / Patel, Bindiben / Giralt, Albert / Canals, Josep M / Memo, Maurizio / Alberch, Jordi / López-Barneo, José / Vila, Miquel / Cuervo, Ana Maria / Tolosa, Eduard / Consiglio, Antonella / Raya, Angel. ·Institute for Biomedicine (IBUB), University of Barcelona, Barcelona, Spain. ·EMBO Mol Med · Pubmed #22407749.

ABSTRACT: Induced pluripotent stem cells (iPSC) offer an unprecedented opportunity to model human disease in relevant cell types, but it is unclear whether they could successfully model age-related diseases such as Parkinson's disease (PD). Here, we generated iPSC lines from seven patients with idiopathic PD (ID-PD), four patients with familial PD associated to the G2019S mutation in the Leucine-Rich Repeat Kinase 2 (LRRK2) gene (LRRK2-PD) and four age- and sex-matched healthy individuals (Ctrl). Over long-time culture, dopaminergic neurons (DAn) differentiated from either ID-PD- or LRRK2-PD-iPSC showed morphological alterations, including reduced numbers of neurites and neurite arborization, as well as accumulation of autophagic vacuoles, which were not evident in DAn differentiated from Ctrl-iPSC. Further induction of autophagy and/or inhibition of lysosomal proteolysis greatly exacerbated the DAn morphological alterations, indicating autophagic compromise in DAn from ID-PD- and LRRK2-PD-iPSC, which we demonstrate occurs at the level of autophagosome clearance. Our study provides an iPSC-based in vitro model that captures the patients' genetic complexity and allows investigation of the pathogenesis of both sporadic and familial PD cases in a disease-relevant cell type.